Keyword: Eli Lilly

Lilly Oncology’s marketing chief has some key words for pharma marketers: Don’t lead with data. Put patients’ insights at the forefront instead.

​​​​​​​But with six months down and six to go, Humira is on track to keep its pharma TV ad crown for 2018 with spending well ahead of 2017.

Roche sued Lilly Tuesday, claiming the two-year-old psoriasis med Taltz steps on one of its patents. Thing is, Roche just won that patent this week.

The North American expansions come amid a restructuring at Evonik, which aims to save €200 million in cost by the end of 2020.

With some new data in hand, Eli Lilly's Taltz looks poised to challenge Novartis' Cosentyx in a third indication.

In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.

Patients on Trulicity were more likely to continue therapy after a year than those on rival meds, according to data presented at ADA.

Invokana carries a warning for amputation risks, but an analysis found the drug lowered heart failure hospitalizations without increasing those risks.

As the psoriatic arthritis field heats up, Novartis has added some new data to its Cosentyx label it hopes can stretch out the drug’s lead.

AbbVie has stored dozens of Humira patents in Bermuda, allowing it to lower its corporate tax rate, according to Reuters.